← Back to Screener
Kamada Ltd (KMDA)
Price$8.24
Favorite Metrics
Price vs S&P 500 (26W)19.41%
Price vs S&P 500 (4W)-7.57%
Market Capitalization$475.33M
P/E Ratio (Annual)23.53x
Indicated Dividend Yield (Annual)2.96%
All Metrics
P/CF (Annual)18.65x
Book Value / Share (Quarterly)$4.66
P/TBV (Annual)2.35x
Indicated Dividend (Annual)$0.20
Revenue Growth (3Y)11.75%
Cash Flow / Share (Quarterly)$0.27
Price vs S&P 500 (YTD)16.90%
Gross Margin (TTM)42.34%
Net Profit Margin (TTM)11.19%
EPS (TTM)$0.35
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$0.35
Revenue Growth (5Y)6.26%
EPS (Annual)$0.35
Dividend / Share (Annual)$0.20
ROI (Annual)7.20%
Gross Margin (Annual)42.34%
Net Profit Margin (5Y Avg)4.42%
Cash / Share (Quarterly)$1.31
P/E Basic Excl Extra (TTM)23.53x
Revenue Growth QoQ (YoY)14.54%
EPS Growth (5Y)-2.02%
P/E Normalized (Annual)23.53x
ROA (Last FY)5.33%
Revenue Growth TTM (YoY)12.12%
EBITD / Share (TTM)$0.66
ROE (5Y Avg)2.78%
Operating Margin (TTM)14.54%
Cash Flow / Share (Annual)$0.27
P/B Ratio1.77x
P/B Ratio (Quarterly)1.51x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.28x
Net Interest Coverage (TTM)206.85x
ROA (TTM)5.39%
EPS Growth QoQ (YoY)-5.53%
EV / EBITDA (TTM)10.69x
EPS Incl Extra (Annual)$0.35
Current Ratio (Annual)4.07x
Quick Ratio (Quarterly)2.28x
3-Month Avg Trading Volume0.08M
52-Week Price Return34.39%
EV / Free Cash Flow (Annual)26.30x
P/E Incl Extra (TTM)23.53x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.00
P/S Ratio (Annual)2.63x
Asset Turnover (Annual)0.48x
52-Week High$9.35
Operating Margin (5Y Avg)7.37%
EPS Excl Extra (Annual)$0.35
CapEx CAGR (5Y)12.39%
Tangible BV CAGR (5Y)-0.48%
26-Week Price Return23.39%
Quick Ratio (Annual)2.21x
13-Week Price Return4.71%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)4.07x
Enterprise Value$411.425
Revenue / Share Growth (5Y)0.70%
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)3.13%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.27x
Pretax Margin (Annual)13.00%
Cash / Share (Annual)$1.31
3-Month Return Std Dev38.32%
Gross Margin (5Y Avg)38.02%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)4.16%
EBITDA Interim CAGR (5Y)17.44%
ROE (Last FY)7.51%
Net Interest Coverage (Annual)12.22x
EPS Basic Excl Extra (Annual)$0.35
P/FCF (TTM)26.97x
Receivables Turnover (TTM)7.43x
EV / Free Cash Flow (TTM)26.30x
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$0.35
Receivables Turnover (Annual)7.32x
ROI (TTM)7.40%
P/S Ratio (TTM)2.63x
Pretax Margin (5Y Avg)4.72%
Revenue / Share (Annual)$3.09
Tangible BV / Share (Annual)$3.00
Forward P/E16.32x
Free OCF CAGR (5Y)2.81%
Price vs S&P 500 (52W)4.56%
P/E Ratio (TTM)23.53x
EPS Growth TTM (YoY)38.30%
Year-to-Date Return19.55%
5-Day Price Return-0.82%
EPS Normalized (Annual)$0.35
ROA (5Y Avg)2.03%
Net Profit Margin (Annual)11.19%
Month-to-Date Return1.20%
Cash Flow / Share (TTM)$0.39
EBITD / Share (Annual)$0.44
Operating Margin (Annual)14.54%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)18.65x
ROI (5Y Avg)2.71%
P/E Excl Extra (TTM)23.53x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.35
P/TBV (Quarterly)2.35x
Payout Ratio (Annual)57.10%
P/B Ratio (Annual)1.51x
Inventory Turnover (TTM)1.27x
Pretax Margin (TTM)13.00%
Book Value / Share (Annual)$4.66
Price vs S&P 500 (13W)4.03%
Net Margin Growth (5Y)-2.71%
Beta0.95x
P/FCF (Annual)30.38x
Revenue / Share (TTM)$2.94
ROE (TTM)7.72%
52-Week Low$6.15
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KMDAKamada Ltd | 2.63x | 12.12% | 42.34% | -2.02% | $8.24 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Kamada Ltd is a biopharmaceutical company that develops and markets plasma-derived protein therapeutics for specialty diseases across multiple therapeutic areas including hemophilia, lung disease, immunoglobulin deficiencies, vaccines, critical care, and diagnostics. The company's proprietary portfolio includes key products such as Glassia, Bramitob, Foster, and Ixiaro. Revenue is primarily generated from proprietary products, with a secondary distribution segment.